References

1. Ottaviani G, Jaffe N. The Epidemiology of Osteosarcoma. In: Jaffe N, Bruland OS, Bielack S, eds. Pediatric and Adolescent Osteosarcoma . Vol 152. Cancer Treatment and Research. Springer US; 2009:3-13. doi:10.1007/978-1-4419-0284-9_12. SEER Program (National Cancer Institute (US)). Cancer Incidence and Survival among Children and Adolescents: United States SEER Program, 1975-1995 . National Cancer Institute; 1999.3. American Cancer Society. Cancer Facts & Figures . The Society; 2008.4. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program.Cancer . 2009;115(7):1531-1543. doi:10.1002/cncr.241215. Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer . 2009;125(1):229-234. doi:10.1002/ijc.243206. Friedman MA, Carter SK. The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol . 1972;4(5‐6):482-510.7. Taran SJ, Taran R, Malipatil NB. Pediatric osteosarcoma: an updated review. Indian J Med Paediatr Oncol . 2017;38(01):33-43.8. Link MP, Goorin AM, Horowitz M, et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity: updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res . 1991;270:8-14.9. Friebele JC, Peck J, Pan X, Abdel-Rasoul M, Mayerson JL. Osteosarcoma: a meta-analysis and review of the literature. Am J Orthop . 2015;44(12):547-553.10. Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. J Clin Oncol . 2015;33(27):3029-3035. doi:10.1200/JCO.2014.59.489511. Beird HC, Bielack SS, Flanagan AM, et al. Osteosarcoma. Nat Rev Dis Primer . 2022;8(1):77. doi:10.1038/s41572-022-00409-y12. Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.Lancet Oncol . 2016;17(10):1396-1408. doi:10.1016/S1470-2045(16)30214-513. Bielack SS, Smeland S, Whelan JS, et al. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. J Clin Oncol . 2015;33(20):2279-2287. doi:10.1200/JCO.2014.60.073414. Tunn PU, Reichardt P. Chemotherapy for Osteosarcoma without High-Dose Methotrexate: A 12-Year Follow-Up on 53 Patients. Oncol Res Treat . 2007;30(5):228-232. doi:10.1159/00010077615. Reed DR, Hayashi M, Wagner L, et al. Treatment pathway of bone sarcoma in children, adolescents, and young adults.Cancer . 2017;123(12):2206-2218. doi:10.1002/cncr.3058916. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German–Austrian–Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol . 1998;9(8):893-899. doi:10.1023/A:100839110313217. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols. J Clin Oncol . 2002;20(3):776-790. doi:10.1200/JCO.2002.20.3.77618. O’Kane GM, Cadoo KA, Walsh EM, et al. Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review. Clin Sarcoma Res . 2015;5(1):17. doi:10.1186/s13569-015-0032-019. Imran H, Enders F, Krailo M, et al. Effect of Time to Resumption of Chemotherapy After Definitive Surgery on Prognosis for Non-Metastatic Osteosarcoma: J Bone Jt Surg-Am Vol . 2009;91(3):604-612. doi:10.2106/JBJS.H.0044920. Halalsheh H, Ismael T, Boheisi M, Shehadeh A, Sultan I. Impact of delay of local control in nonmetastatic extremity primary osteosarcoma.Pediatr Blood Cancer . 2024;71(1):e30752. doi:10.1002/pbc.30752